New in AML
Our "New in AML" articles cover treatment option updates, coverage of advancements from major AML academic meetings, and more.
mds, aml, life with aml, new in aml, Bemcentinib and aml, trials for aml
Dr. Chandhok is doing important research into improving drug efficacy for underserved populations.
The menin protein is an important factor in both KMT2A and NPM1 versions of AML.
The U.S. Food and Drug Administration (FDA) grants approval for a new therapy called quizartinib for FLT3 positive acute myeloid leukemia.
HealthTree spoke with Dr. Loh at ASCO 2023 about the importance of shared decision making for AML patients.
HealthTree spoke with Dr. Pardee at ASCO 2023 about his early research looking at a possible new drug option for those with P53 mutated AML.
HealthTree spoke with Dr. Swoboda at ASCO 2023 about the important work he is doing on AML at Tampa General Hospital.
For more than 30 years, umbilical cord blood (UCB) has been an important stem cell source for patients with leukemia, lymphoma and MDS
Residual disease may still be present even when a patient is considered “in remission”. Lingering traces of leukemia make a transplant less effective.
The work Dr. Tinsley-Vance is doing is important and will have a big impact on the way we look at patient decision making and our support of caregivers.